Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

Published:2015-12 Issue:1 Volume:13 Page:
ISSN:1741-7015
Container-title:BMC Medicine
language:en
Short-container-title:BMC Med

Author:

Prat Aleix^ORCID,Fan Cheng,Fernández Aranzazu,Hoadley Katherine A.,Martinello Rossella,Vidal Maria,Viladot Margarita,Pineda Estela,Arance Ana,Muñoz Montserrat,Paré Laia,Cheang Maggie C. U.,Adamo Barbara,Perou Charles M.

Funder

NCI Breast Spore

National Cancer Institute

Instituto de Salud Carlos III

Susan Komen Foundation

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12916-015-0540-z.pdf

Reference43 articles.

1. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2012;9:48–57.

2. Prat A, Galván P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, et al. Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay. Clin Cancer Res 2015. In Press.

3. Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.

4. Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.

5. Martín M, Prat A, Rodríguez-Lescure Á, Caballero R, Ebbert MT, Munárriz B, et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013;138:457–66.

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy;The Breast;2024-12

2. TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts;Translational Oncology;2024-10

3. Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes;Journal of Clinical Investigation;2024-09-03

4. Hormone receptor-positive early breast cancer in young women: A comprehensive review;Cancer Treatment Reviews;2024-09

5. Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?;ESMO Open;2024-09